Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02448797
Recruitment Status : Recruiting
First Posted : May 19, 2015
Last Update Posted : April 18, 2019
Sponsor:
Information provided by (Responsible Party):
Betta Pharmaceuticals Co., Ltd.

Brief Summary:
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. The primary endpoint is disease-free survival.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: Icotinib Drug: Chemotherapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)
Study Start Date : May 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: icotinib
125 mg three times daily (375 mg per day) orally for two years.
Drug: Icotinib
125 mg three times daily (375 mg per day) orally for two years.
Other Name: Conmana

Active Comparator: standard chemotherapy

Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.

cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.

For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles.

Drug: Chemotherapy
Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles.
Other Names:
  • Navelbine
  • ALIMTA




Primary Outcome Measures :
  1. disease free survival [ Time Frame: 48 months ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: 60 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically confirmed non-small cell lung cancer after surgical resection
  • Stage II-IIIA disease according to 7th edition of TNM staging
  • Positive EGFR gene mutation (19/21)
  • ECOG 0-1
  • At least 1-year life expectancy
  • Adequate organ function

Exclusion Criteria:

  • Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Pneumonectomy of right lung
  • Any unresolved chronic toxicity from previous anticancer therapy
  • Allergic to study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448797


Contacts
Layout table for location contacts
Contact: Caicun Zhou, MD 13301825532
Contact: Jianxing He, MD 13802777270

Locations
Layout table for location information
China, Beijing
307 Hospital of PLA Recruiting
Beijing, Beijing, China, 100071
Principal Investigator: Xiao-qing Liu, M.D.         
China, Fujian
Fujian Provincal Cancer Hospital Recruiting
Fuzhou, Fujian, China, 350014
Contact: Huang Cheng, M.D.    0086-13905010397      
Principal Investigator: Huang Cheng, M.D.         
China, Guangdong
The First Affiliated Hospital Of Guangzhou Medical Collage Recruiting
Guangzhou, Guangdong, China, 510120
Contact: He Jianxing    0086-13802777270      
Principal Investigator: He Jianxing, M.D.         
Shenzhen People's Hospital Recruiting
Shenzhen, Guangdong, China, 518020
Contact: Zheng Wang, MD    13502886638      
Principal Investigator: Zheng Wang, MD         
China, Liaoning
The First Hospital of China Medical University Recruiting
Shenyang, Liaoning, China, 110001
Contact: Liu Yunpeng, M.D.    0086-13898865122      
Principal Investigator: Liu Yunpeng, M.D.         
First Affiliated Hospital of China Medical University Active, not recruiting
Shenyang, Liaoning, China, 150081
China, Shanghai
Shanghai Pulmonary Hospital Recruiting
Shanghai, Shanghai, China, 200433
Principal Investigator: Cai-Cun Zhou         
China, Zhejiang
The First Affiliated Hospital of Medical School of Zhejiang University Recruiting
Hangzhou, Zhejiang, China, 310000
Contact: Zhou Jianying, M.D.    0086-13750881678    drzjy@163.com   
Principal Investigator: Zhou Jianying, M.D.         
Sponsors and Collaborators
Betta Pharmaceuticals Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Caicun Zhou, MD Shanghai Pulmonary Hospital, Shanghai, China
Study Chair: Jianxing He, MD The First Affiliated Hospital of Guangzhou Medical University

Layout table for additonal information
Responsible Party: Betta Pharmaceuticals Co., Ltd.
ClinicalTrials.gov Identifier: NCT02448797    
Other Study ID Numbers: BD-IC-IV-61
CCTC-1501 ( Other Identifier: China Clinical Trial Consortium )
First Posted: May 19, 2015    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Cisplatin
Antineoplastic Agents